SCHEMBL5585348

SCHEMBL5585348

NC(=O)N1CCN(c2ccccc2)C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.62
NPC1 O15118 1/20 0.62
RAB9A P51151 1/20 0.62
KMT2A Q03164 1/20 0.62
NTRK1 P04629 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43
SIGMAR1 Q99720 2/20 0.42
PRMT1 Q99873 1/20 0.42
HDAC1 Q13547 3/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
F10 P00742 2/20 0.39
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
F2 P00734 1/20 0.39
PRSS1 P07477 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13927746 0.84 NPC1 (0.60) MEN1NPC1RAB9AKMT2ANTRK1
SCHEMBL15328003 0.83 DRD2 (0.46) MEN1NPC1RAB9AKMT2ADRD2
SCHEMBL15328043 0.83 DRD2 (0.46) MEN1NPC1RAB9AKMT2ADRD2
SCHEMBL13926363 0.83 RAB9A (0.50) MEN1NPC1RAB9AKMT2ADRD2
SCHEMBL15328097 0.82 HTR2A (0.54) DRD2DRD3PRMT1ALDH1A1
SCHEMBL11861565 0.82 KMT2A (0.62) MEN1NPC1RAB9AKMT2ANTRK1
SCHEMBL10202845 0.82 NPC1 (0.62) MEN1NPC1RAB9AKMT2ANTRK1
SCHEMBL2670692 0.82 NPC1 (0.62) MEN1NPC1RAB9AKMT2ANTRK1
SCHEMBL17993502 0.81 DRD2 (0.50) MEN1NPC1RAB9AKMT2ADRD2
SCHEMBL172003 0.81 KMT2A (0.46) MEN1NPC1RAB9AKMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US claimed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US claimed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed
WO-2013044361-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 MEN1 3655/4885NPC1 1129/4885RAB9A 2065/4885
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 MEN1 1573/4885NPC1 3108/4885RAB9A 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.